Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364903 | 0.91 | ATM (0.44) | TXNRD1HCAR2ATMMAPTRAB9A | |
| SCHEMBL18364443 | 0.87 | ATM (0.41) | TXNRD1HCAR2ATMMAPTRAB9A | |
| SCHEMBL18364444 | 0.85 | HCAR2 (0.40) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL18364421 | 0.85 | ATM (0.44) | TXNRD1HCAR2ATMMAPTRAB9A | |
| SCHEMBL18364413 | 0.84 | HCAR2 (0.39) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL18352686 | 0.79 | ATM (0.47) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL18364409 | 0.77 | EPHX1 (0.39) | HCAR2ATMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18364460 | 0.77 | NPY5R (0.46) | MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL18354879 | 0.77 | ATM (0.42) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL18364888 | 0.76 | ATM (0.44) | HCAR2ATMMAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | TXNRD1 271/4885HCAR2 290/4885ATM 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.